Back to Journals » OncoTargets and Therapy » Volume 6

Update of research on the role of EZH2 in cancer progression

Authors Shen L, Cui J, Liang S, Pang Y, Liu P

Received 7 January 2013

Accepted for publication 17 February 2013

Published 4 April 2013 Volume 2013:6 Pages 321—324

DOI https://doi.org/10.2147/OTT.S42453

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5


Liang Shen,1 Jing Cui,2 Shumei Liang,3 Yingxin Pang,1 Peishu Liu1

1Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 2Department of Oral and Maxillofacial Surgery, Jinan Stomatologic Hospital, 3Department of Obstetrics and Gynecology, Provincial Hospital Affiliated to Shandong University, Jinan, People’s Republic of China

Abstract: Accumulating evidence shows that enhancer of zeste homolog 2 (E2H2) is upregulated in a broad range of cancer types, such as breast cancer, prostate cancer, ovarian cancer, and colon cancer. Therefore, inhibiting EZH2 expression may be a promising strategy for anticancer therapy. This review focuses on the current understanding of the mechanisms underlying EZH2 regulation that are involved in cancer progression. Also, it introduces two EZH2 inhibitors that target EZH2 and could be potentially applied in the treatment of cancer in the future.
Keywords: EZH2, PRC2, cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]